title: Current management of small cell lung cancer.
abstract: Confined to one side of the chest, limited stage small cell lung cancer is treated with a combination of chemotherapy and radiotherapy, yet has a long-term survival rate of only 15%. Extensive stage disease has initial response rates to chemotherapy exceeding 70%. However, the disease almost invariably progresses and becomes fatal. Many recent clinical trials have failed to show superiority of newer chemotherapeutics or targeted therapies compared with the standard chemotherapy backbone of platinum plus etoposide. Numerous promising targeted therapies and other agents are still in development.
authors: Stanford Cancer Institute, Department of Medicine, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305-5826, USA. jwneal@stanford.edu
authors: Joel W
authors: JW
authors: Neal
authors: Matthew A
authors: MA
authors: Gubens
authors: Heather A
authors: HA
authors: Wakelee
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D059248:Chemoradiotherapy; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D011013:Pneumonectomy; D055752:Small Cell Lung Carcinoma / Q000175:diagnosis / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents